Sort
15,273 grants matching “antimicrobial resistance”
Determinants of H. influenzae Virulence in Otitis Media
$626,261Lauren O Bakaletz · Research Inst Nationwide Children'S Hosp · R01 · FY2021 · DC
Multi-component chlorination intervention to reduce neonatal infections in rural health facilities
$626,025Amy J. Pickering · University Of California Berkeley · R01 · FY2025 · AI
Emerging multidrug resistance mechanisms in Campylobacter
$626,007Qijing Zhang · Iowa State University · R01 · FY2024 · AI
Hydrogel Delivery of Bacteriophage to Treat Wound Infections
$625,909Paul L Bollyky · Stanford University · R01 · FY2025 · EB
Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation
$625,684Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · AI
Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation
$625,684Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2019 · AI
EMERGEncy ID Net Study
$625,544David Andrew Talan · Olive View-Ucla Education And Res Inst · U01 · FY2008 · CI
Toward novel therapies against Lyme disease through the inhibition of lysinoalaine cross-linking in the bacterial flagella.
$625,469Brian R Crane · Cornell University · R01 · FY2021 · AI
Molecular Analysis of Host Immune Response in Leprosy
$625,453Robert L Modlin · University Of California Los Angeles · R01 · FY2015 · AI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach
$625,436Gauri G Rao · Univ Of North Carolina Chapel Hill · R01 · FY2022 · AI
Antimicrobial evaluation and development
$625,411Kim Lewis · Northeastern University · P01 · FY2019 · AI
Transcription Termination and its Regulation in E. coli
$625,372Evgeny Nudler · New York University School Of Medicine · R01 · FY2008 · GM
Anti-infectives that target bacterial ribosomes
$625,367Wayne State University · U01 · FY2005 · AI
A mechanistic approach to intercalated cell phagocytosis
$625,300Andrew Lawrence Schwaderer · Indiana University Indianapolis · R01 · FY2024 · DK
Post-PCV pneumococcal population genetics and resistance
$625,126Jonathan A Finkelstein · Harvard Pilgrim Health Care, Inc. · R01 · FY2007 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE FARM-RAISED CATFISH INDUSTRY DOMINATES THE AQUACULTURE SECTOR IN THE UNITED STATES AND IS AN IMPORTANT ECONOMIC COMPONENT OF MISSISSIPPI, ALABAMA, AND ARKANSAS. EDWARDSIELLA ICTALURI IS A SIGNIFICANT PATHOGEN CAUSING ENTERIC SEPTICEMIA OF CATFISH (ESC). THERE ARE LIMITATIONS IN THE CURRENT THERAPEUTIC AND PREVENTATIVE STRATEGIES AGAINST ESC. THE PROBLEM IS EXACERBATED BY THE INCREASING EMERGENCE OF E. ICTALURI STRAINS RESISTANT TO THE APPROVED ANTIMICROBIALS. AS A RESULT, THERE IS AN URGENT, INDUSTRY-DEFINED NEED TO PROVIDE CATFISH PRODUCERS WITH A PRACTICAL, SAFE, AND EFFICACIOUS TREATMENT ALTERNATIVE. THIS PROPOSAL FOCUSES ON THE APPLICATION OF TRANS-CINNAMALDEHYDE (TC) AS A POSSIBLE SOLUTION TO CONTROL ESC INFECTION. TC IS A COMPOUND APPROVED AS A FOOD ADDITIVE BY THE U.S. FDA. OUR PRELIMINARY RESULTS AND PUBLISHED RESEARCH DEMONSTRATED THAT TC IS EFFECTIVE IN INHIBITING THE GROWTH OF E. ICTALURI, INCLUDING MDR STRAINS.THIS PROJECT INCLUDES CONDUCTING RESEARCH TO INVESTIGATE THE THERAPEUTIC AND PROPHYLACTIC POTENTIAL OF DIETARY-TC IN CATFISH AGAINST E. ICTALURI INFECTION, INCLUDING MULTIDRUG-RESISTANT (MDR) STRAINS. POND STUDIES WILL BE CONDUCTED TO TEST THE EFFICACY OF TC UNDER COMMERCIAL CONDITIONS. RESEARCH IN THIS PROJECT WILL ASSESS WHETHER TC IMPROVES PHAGOCYTIC AND BACTERICIDAL ACTIVITY OF MACROPHAGES AGAINST E. ICTALURI. WE WILL TEST ANOTHER PROTECTION MECHANISM OF DIETARY-TC AGAINST E. ICTALURI THROUGH IMPROVING INTESTINAL INNATE IMMUNE RESPONSE. THE STUDY ALSO INCLUDES AN ASSESSMENT OF THE POTENTIAL FOR E. ICTALURI TO DEVELOP RESISTANCE TO TC AND INVESTIGATE THE POSSIBLE MECHANISM OF TC ANTIBACTERIAL ACTION.THE ULTIMATE OUTCOME OF THIS PROJECT IS TO DEVELOP A MANAGEMENT STRATEGY TO CONTROL ESC INFECTION AND MINIMIZE AM USE IN CATFISH AQUACULTURE. WE EXPECT THAT APPLICATION OF TC AS A FEED ADDITIVE (POTENTIALLY PRODUCED BY COMMERCIAL FEED MILLS FOR SALE TO CATFISH PRODUCERS) WILL REDUCE THE MORTALITIES ASSOCIATED E. ICTALURI INFECTIONS AND WILL REDUCE COSTS AND THE CONSEQUENCES ASSOCIATED WITH SPREAD OF MDR STRAINS. THE APPROACH IMPLEMENTED IN THIS RESEARCH WILL ENSURE AQUACULTURE PRODUCERS HAVE ADEQUATE TREATMENT OPTIONS FOR MAXIMUM PRODUCTION EFFICIENCY, PROFITABILITY, AND SUSTAINABILITY.
$625,000Mississippi State University · · FY2022 · National Institute of Food and Agriculture
Antimicrobial Tracheostomy Tube to Prevent Biofilm and Reduce InfectionRisks
$624,941Jennifer Ann Neff · Allvivo Vascular, Inc. · R44 · FY2019 · HL
Trial of Metformin for TB/HIV Host-directed Therapy
$624,591Hardy Kornfeld · Univ Of Massachusetts Med Sch Worcester · U01 · FY2024 · AI
STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES
$624,437Peter Myler · Seattle Children'S Hospital · N01 · FY2019 · AI
SIS multicenter study of duration of antibiotics for intraabdominal infection
$624,398Robert G Sawyer · University Of Virginia · R01 · FY2008 · GM
Syphilis Immunology and Biology to Improve Clinical Management and Vaccine Design
$624,293Jeffrey David Klausner · University Of Southern California · R01 · FY2021 · AI
Breaching the Gram negative bacterial cellular envelope
$624,267Yinan Wei · Texas A&M University Health Science Ctr · R01 · FY2025 · AI
Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
$623,944Lisa E Manhart · University Of Washington · R01 · FY2024 · AI
Prevention of Infection in Indian Neonates
$623,903University Of Maryland Baltimore · U01 · FY2001 · HD
Next-generation 5-nitro heterocyclic antimicrobials against mucosal protists
$623,681Lars Eckmann · University Of California, San Diego · R01 · FY2019 · AI